Island Pharmaceuticals posts wider half-year loss despite uptick in asset backing

An announcement from Island Pharmaceuticals Ltd ( (AU:ILA) ) is now available.

Island Pharmaceuticals Limited reported a sharp increase in its half-year loss for the period ended 31 December 2025, with the loss after tax widening to $4.81 million from $1.53 million a year earlier. Despite the deeper loss, net tangible assets per ordinary security improved to 2.37 cents from 2.14 cents, and the board maintained its stance of not paying or recommending dividends for either the current or prior comparable period.

The company reported no changes in control over entities, no associates or joint ventures, and no dividend reinvestment plan in place, underscoring a relatively straightforward corporate structure during the half-year. The financial statements for the period were reviewed by the company’s auditors, and the half-year report was authorised for release by the board, signalling continued regulatory compliance but also highlighting ongoing losses that shareholders will be monitoring closely.

The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.

More about Island Pharmaceuticals Ltd

Island Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing pharmaceutical products, although the half-year report provides only limited operational detail. The company is listed and operates in the life sciences sector, reporting financial performance metrics such as net tangible assets per share as part of its regular disclosures to investors and regulators.

Average Trading Volume: 395,797

Technical Sentiment Signal: Buy

Current Market Cap: A$109.1M

See more insights into ILA stock on TipRanks’ Stock Analysis page.